Handelsavisen
prelaunch
Companies Healthcare OCAXX.AX
OC
OCAXX.AX ASX Healthcare Facilities & Services

Ocaxx.Ax

A$0,58
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-15,5 %
ROE
2,8 %
Net margin
11,7 %
Debt / equity
0,58
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

OCAXX.AX operates in the healthcare sector, focusing on biotechnology and healthcare facilities and services, generating revenue primarily through its operations in this field.

Business. OCAXX.AX operates in the healthcare sector, focusing on biotechnology and healthcare facilities and services, generating revenue primarily through its operations in this field.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
BUY5 analysts
3 buy2 hold0 sell
Avg 12m price target0,96

Analyst recommendations

5 analysts · consensus Buy
Buy3
Hold2
Sell0
12-month price target
0,96
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
5 analysts · indicative
Ownership
not yet wired
Profitability
2,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning OCAXX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to OCAXX.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    OCAXX.AX operates in the healthcare sector, focusing on biotechnology and healthcare facilities and services, generating revenue primarily through its operations in this field.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.58, indicating a moderate level of leverage. Despite a negative operating income of -40,328,000 NZD, the company reported a net income of 30,415,000 NZD, suggesting effective cost management or non-operating income sources. The company's liquidity position is assessed as medium, with a cash and equivalents balance of 7,589,000 NZD, which is significantly lower than its long-term debt of 638,306,000 NZD.

    In terms of profitability, the company's return on equity (ROE) is 2.76%, and its return on assets (ROA) is 1.03%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of generating returns from equity and assets.

    The company's revenue is concentrated in a single segment, as no specific segments are disclosed, and there is no geographic breakdown provided. This lack of diversification could pose a risk if the company's primary market experiences a downturn.

    The company's growth trajectory is uncertain, as there is no specific outlook provided for the current or next fiscal year. However, the company's operating cash flow of 110,277,000 NZD and free cash flow of 12,325,000 NZD suggest some capacity for reinvestment or debt reduction.

    The company faces a medium liquidity risk, as its cash and equivalents are insufficient to cover its long-term debt. Additionally, the dilution risk could not be assessed due to missing basic and diluted share counts. The company's capital expenditure of -40,238,000 NZD indicates a reduction in capital spending, which could affect future growth.

    Recent events and filings do not provide specific details, but the company's financial snapshot indicates a need for careful monitoring of its liquidity and debt management strategies.

    Key takeaways
    • The company has a moderate level of leverage with a debt-to-equity ratio of 0.58.
    • Despite a negative operating income, the company reported a net income, indicating effective cost management.
    • The company's ROE and ROA are below the industry median, suggesting underperformance in generating returns.
    • The company's liquidity position is medium, with cash and equivalents significantly lower than long-term debt.
    • The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year.
    • The company's capital expenditure has decreased, which could impact future growth.
    • **margin_outlook_rationale**: The company's margin outlook is uncertain due to a negative operating income and a net income that is significantly lower than the operating loss.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    A$0,58
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    A$1.10B
    Net cash
    -A$630.7M
    Current ratio
    Debt / equity
    0.6
    ROA
    1.0%
    ROE
    2.8%
    Cash conversion
    363.0%
    CapEx / revenue
    -15.4%
    SBC / revenue
    Dilution ratio

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,08
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    5
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-04 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,08
    Revenueno estimateno estimate380,3M NZD
    Operating incomeno estimateno estimate87,7M NZD
    Full-year consensus mean (period as reported by source) · consensus in NZD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution5 analysts
    Strong buy0
    Buy3
    Hold2
    Sell0
    Strong sell0
    12-month price targetA$0,96 · Median A$1,00
    Low A$0,84High A$1,04
    Operating income · consensus87,7M NZD
    EPS surprise
    −11,0 %
    reported vs consensus · miss
    Revenue surprise
    −6,5 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowA$0,84
    MeanA$0,96
    MedianA$1,00
    HighA$1,04
    SpotA$0,58
    +66.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskUnknown
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-15,5 %Bottom quartile
    Net Margin11,7 %Above P75
    ROE2,8 %Below median
    Capex / Rev-15,4 %Below median
    D/E0,58Below median
    Cash Conv3,63Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • OCAXX.AX Market data — financials · 2026-05-28
    • Oceania Healthcare Ltd Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    OCAXX.AXCanonical
    ASX · AUD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskUnknown
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage